DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution. “Eton’s addition to the Russell 2000 and Russell 3000 Indexes is a signi ...

I hold a PhD in Machine Learning focused on Economics and Finance and have academic affiliations with IESE Business School, ESADE Business School, and the Barcelona Supercomputing Center. My professional experience includes working at Deloitte Financial Advisory, specializing in banking and mergers & acquisitions. My interests broadly span machine learning and generative AI applications in finance and economics, and I am proficient in Python, R, and SQL.Analyst’s Disclosure:I/we have no stock, option or sim ...

Eton Pharmaceuticals, Inc. (ETON) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

文章核心观点 Eton公司宣布其KHINDIVI获FDA批准用于5岁及以上肾上腺皮质功能不全儿科患者替代疗法，预计6月第一周商业推出，与ALKINDI SPRINKLE组合峰值销售额超5000万美元，为患者提供新治疗选择 [1][6] 产品信息 KHINDIVI - 是唯一获FDA批准的氢化可的松口服溶液，1mg/ml浓度，无需分割或压碎药片，无需冷藏、混合或摇晃，方便准确给药，适用于吞咽困难或有特殊给药需求患者 [1][2] - 用于5岁及以上肾上腺皮质功能不全儿科患者替代疗法，不可用于应激或急性事件时增加剂量 [9][10] ALKINDI SPRINKLE - 是FDA批准用于肾上腺皮质功能不全儿科患者的氢化可的松口服颗粒 [5] - 用于肾上腺皮质功能不全儿科患者替代疗法 [40] 公司情况 - Eton是专注开发和商业化罕见病治疗药物的创新制药公司，现有8种商业罕见病产品，另有5种后期开发候选产品 [41] - 公司预计KHINDIVI和ALKINDI SPRINKLE组合峰值销售额超5000万美元/年 [6] - KHINDIVI将由公司现有儿科内分泌罕见病专家团队推广，通过Anovo药房独家供应，Anovo将与公司合作实施Eton Cares计划，为符合条件患者提供共付援助 [5][7][8] 各方观点 公司CEO - FDA批准KHINDIVI是公司巨大成就，体现公司执行卓越，商业团队准备好在获批第一周推广该产品 [3][4] 医学教授 - 精准一致的氢化可的松给药对管理儿科肾上腺皮质功能不全很重要，FDA批准的口服氢化可的松溶液为医生准确给药提供新工具 [5] 基金会执行董事 - KHINDIVI推出是重大进展，准确分割药片给药一直是难题，准确给药对治疗结果至关重要，赞扬公司使该疗法可通过专业渠道获取 [5] 联系方式 - 投资者联系Lisa M. Wilson，电话212 - 452 - 2793，邮箱lwilson@insitecony.com [43] - 媒体联系Eliza Schleifstein，电话917 - 763 - 8106，邮箱eliza@schleifsteinpr.com [43]

My handle is the Michigan Value Investor, but everyone calls me MVI. I have a PhD in theoretical physics from UC Berkeley and worked briefly in the field before switching my interests to investing. I worked as an analyst at a billion dollar fund for several years before starting my own very small fund in 2009. During this time I have developed a group of stocks that I understand well, and I have excellent relations with management in many cases. This long standing familiarity with a select group of companie ...

DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows: The 25th Annual B. Riley Securities Investor ConferenceDate: Thursday, May ...

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.02, delivering no surprise.Over the last four quarters, the company has s ...

Eton Pharmaceuticals (ETON) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants David Krempa - Chief Business OfficerSean Brynjelsen - CEO & DirectorJames Gruber - CFO Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareMadison Elsaadi - Equity Research Analyst - HealthcareSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Good afternoon, and welcome to the InPharmaceuticals First Quarter twenty twenty five Financial Results ...

Eton Pharmaceuticals (ETON) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants David Krempa - Chief Business OfficerSean Brynjelsen - CEO & DirectorJames Gruber - CFO Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareMadison Elsaadi - Equity Research Analyst - HealthcareSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Good afternoon, and welcome to the InPharmaceuticals First Quarter twenty twenty five Financial Results ...